Human papillomavirus (HPV) can drive tumor development in some rare sinonasal squamous cell carcinomas (SNSCCs), according to ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer, compared with palbociclib and ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests. The treatment could also delay the need for gruelling chemotherapy, ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

PIK3CA mutations are frequently associated with breast cancer with a prevalence of around 40%. These are somatic mutations that code for PI3 kinases, and this, along with Akt and mTOR signaling ...

PIK3CA gene encodes the p110α catalytic subunit of PI3K, which regulates the PI3K/AKT/mTOR signaling pathway. PIK3CA gene mutation is one of the most common mutations in colorectal cancer (CRC), ...

Andreas Varkaris, MD, PhD, discusses PIK3CA mutations in breast cancer and the novel therapies being developed to treat these tumors. Andreas Varkaris, MD, PhD, attending physician and investigator, ...